The efficacy and safety of iGlarLixi versus IDegAsp in Chinese patients with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: Interpretation of the Soli-D study
10.3760/cma.j.cn311282-20241112-00538
- VernacularTitle:浅析Soli-D研究：iGlarLixi与IDegAsp在口服降糖药血糖控制不佳的中国2型糖尿病患者中的疗效和安全性对比
- Author:
Xiaoyuan HUYAN
1
;
Bing LI
;
Weijun GU
;
Yiming MU
Author Information
1. 解放军总医院第二医学中心保健一科，国家老年疾病临床研究中心，北京 100853
- Publication Type:Journal Article
- Keywords:
Chinese population;
Diabetes mellitus, type 2;
iGlarLixi;
Glycaemic control
- From:
Chinese Journal of Endocrinology and Metabolism
2025;41(1):28-32
- CountryChina
- Language:Chinese
-
Abstract:
This article discusses the design, key findings and implications of a recent paper published in Diabetes, Obesity and Metabolism titled "The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial" . This study is the first randomized, active-controlled, phase Ⅲ study comparing the efficacy and safety of iGlarLixi versus IDegAsp in Chinese patients with type 2 diabetes. It offers new evidence for initiating injection therapy in Chinese patients with type 2 diabetes who are inadequately controlled with oral antidiabetic drugs.
